Malopolskie Centrum Kliniczne
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Malopolskie Centrum Kliniczne is evaluating targeted therapies to improve prevention and treatment of heart‑related conditions, with a focus on safety and efficacy.
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Coronary Heart Disease
- Major Adverse Cardiovascular Events (MACE)
Across its 27 trials, the site aims to lower cardiovascular risk and enhance long‑term outcomes for patients.
Digestive System Diseases
Researchers at the centre are testing novel agents for inflammatory bowel conditions, seeking better disease control and quality of life.
- Moderate to Severe Crohn’s Disease
The studies contribute to a growing portfolio of 27 clinical investigations conducted by nine investigators.
Immune System Diseases
The hospital focuses on immune‑modulating therapies for a range of autoimmune disorders, aiming to reduce disease activity and improve patient wellbeing.
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Sjögren’s Syndrome
- Systemic Sclerosis (including diffuse cutaneous form)
- Idiopathic Inflammatory Myopathy (Dermatomyositis/Polymyositis)
- Atopic Dermatitis
- Non‑segmental Vitiligo
These trials explore safety, efficacy and mechanistic profiles of emerging treatments within the broader 27‑trial program.
Musculoskeletal Diseases
Studies target joint and spine disorders, evaluating new drugs that aim to halt progression and relieve pain.
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Axial Spondyloarthritis
- Active Psoriatic Arthritis
The research supports improved therapeutic options for patients with chronic musculoskeletal inflammation.
Nervous System Diseases
The centre investigates treatments for neuropathic pain, aiming to provide relief through innovative pharmacologic approaches.
- Diabetic Peripheral Neuropathic Pain
These efforts are part of the broader clinical portfolio addressing unmet needs in neurological conditions.
Respiratory Tract Diseases
Clinical work includes assessment of inhaled therapies to enhance lung function and reduce exacerbations in chronic airway disease.
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Bronchitis
The trials aim to improve respiratory outcomes for patients with long‑term pulmonary impairment.
Skin and Connective Tissue Diseases
Research focuses on skin‑directed treatments for inflammatory and autoimmune skin conditions, seeking symptom reduction and disease remission.
- Atopic Dermatitis
- Non‑segmental Vitiligo
- Diffuse Cutaneous Systemic Sclerosis
- Systemic Sclerosis
These investigations contribute to the centre’s commitment to advancing care for complex dermatologic disorders.
Immune System Phenomena
The site explores fundamental immune system processes underlying autoimmunity, supporting the development of targeted interventions.
- Immune modulation in Psoriatic Arthritis
- Cytokine pathways in Rheumatoid Arthritis
- B‑cell activity in Sjögren’s Syndrome
Insights gained help refine therapeutic strategies across multiple autoimmune diseases.
Immune System Processes
Investigations aim to characterize cellular and molecular mechanisms driving chronic inflammation, informing future drug design.
- JAK/STAT signaling inhibition
- LPAR1 antagonism in systemic sclerosis
- IL‑23/IL‑17 axis targeting in psoriasis and PsA
Findings from these studies bolster the centre’s role in pioneering immune‑focused clinical research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Cullinan Therapeutics Inc.3active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG7trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Malopolskie Centrum Kliniczne
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1b Open-Label Study to Evaluate the Safety and Efficacy of CLN-978 in Patients with Moderate to Severe Systemic Lupus Erythematosus | Cullinan Therapeutics Inc. | Phase I | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Risankizumab | 4 | Unknown | 2019-05-09 | 2025-03-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.